Overall proportion of industry and non-industry income is: 86.4% industry income vs 13.6% non-industry income. Please find below a list of Industry Partners and related contributions for the financial year 2019:

Industry1 related income (2019)

  Name of company/funder Amount of income2 Percentage of overall budget
  Almirall € 10,000 0,8%
  Biogen € 150,055 12,4%
  Bristol-Myers-Squibb (BMS - formerly Celgene) € 167,796 0,9%
  Canopy Growth € 11,310 13,6%
  Icometrix € 5,000 0,4%
  MedDay € 15,000 1,2%
  Merck € 159,710 13,2%
  Mylan € 30,000 2,5%
  Novartis € 241,222 19,9%
  Quanterix € 5,000 0,4%
  Roche € 117,000 9,7%
  Sanofi-Genzyme € 136,800 11,3%
  Subtotal € 1,211,105 86,4%
[1] Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.
[2] This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

Code of Conduct

On a regular basis, EMSP also collaborates with the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Our approach is transparent and rules-based, as set out in our Code of Conduct.



Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus eros tortor, molestie in ligula quis, condimentum iaculis metus. Suspendisse lacus lacus, auctor sed nisi ac, bibendum ultrices tellus. Suspendisse quis enim ut arcu mattis accumsan sed id lorem. Ut finibus orci dolor, ac sodales diam tincidunt in.